Department of Gastric Surgery, Fujian Medical University Union Hospital, No.29 Xinquan Road, Fuzhou, 350001, Fujian Province, China.
Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Surg Endosc. 2018 Mar;32(3):1495-1505. doi: 10.1007/s00464-017-5837-x. Epub 2017 Sep 15.
To investigate oncologic efficacy of prophylactic laparoscopic superior mesenteric vein (No. 14v) lymph node (LN) dissection for lower-third gastric cancer (LTGC).
We retrospectively collected data from 757 patients who underwent laparoscopic-assisted distal gastrectomy for LTGC. Of these patients, 102 underwent 14v LN dissection (14vD+ group), and the remaining 655 patients did not undergo 14v LN dissection (14vD- group). The outcomes were compared using a 1:1 propensity score matching method.
After matching, 93 patients from the 14vD+ group and 93 patients from the 14vD- group with similar clinicopathological characteristics were compared. Before matching, the overall survival (OS) was similar between the two groups (P = 0.742). After matching, the OS was greater in the 14vD+ group (P = 0.025). The status of 14v dissection was not a significant prognostic factor in the survival analyses, both before and after matching. However, a stratified analysis according to the independent factors in the OS showed that the OS in the 14vD+ group was higher than that in the 14vD- group for cT2-3 patients after matching. The forest plot of OS showed that after matching the 14vD+ group had a significantly higher 3-year OS rate than the 14vD- group in cT2-3 patients. The distribution of the therapeutic index demonstrated that the index of 14v LN was similar to those of Nos. 1, 7, 8a, 9, and 11p after matching.
Adding laparoscopic 14v dissection for laparoscopic-assisted radical distal gastrectomy was safe and might improve the OS for clinically advanced LTGC without serosal invasion.
探讨预防性腹腔镜肠系膜上静脉(No.14v)淋巴结(LN)清扫术治疗胃下三分之一癌(LTGC)的肿瘤学疗效。
我们回顾性收集了 757 例接受腹腔镜辅助远端胃切除术治疗 LTGC 的患者数据。其中 102 例行 14vLN 清扫术(14vD+组),其余 655 例未行 14vLN 清扫术(14vD-组)。采用 1:1 倾向评分匹配法比较两组患者的疗效。
匹配后,14vD+组 93 例患者与 14vD-组 93 例患者的临床病理特征相似。匹配前,两组患者的总生存期(OS)相似(P=0.742)。匹配后,14vD+组患者的 OS 更大(P=0.025)。14v 清扫状态在生存分析中不是一个显著的预后因素,匹配前后均如此。然而,根据 OS 中的独立因素进行分层分析显示,匹配后 cT2-3 患者的 14vD+组 OS 高于 14vD-组。OS 的森林图显示,匹配后 cT2-3 患者的 14vD+组 3 年 OS 率明显高于 14vD-组。治疗指数的分布表明,14vLN 指数与 No.1、7、8a、9 和 11p 指数相似,匹配后亦然。
对于临床进展期未侵犯浆膜的 LTGC,在腹腔镜辅助根治性远端胃切除术中附加腹腔镜 14v 清扫术是安全的,可能提高患者的 OS。